Pfizer and BioNTech Granted EUA for Booster Dose of COVID-19 Vaccine in Young Children
Should be administered at least five months after the second dose of the two-dose primary series
Pfizer and BioNTech announced that FDA has expanded emergency use authorization (EUA) to include a booster dose after completion of the primary series of the companies’ COVID-19 vaccine in children five through 11 years of age. The booster dose should be given at least five months after the second dose of the two-dose primary series. More than 8 million children aged 5–11 years old have completed a primary series of the vaccine in the United States to date.
The EUA is based on data that show children five through 11 years of age had a significant immune response following a booster dose of the vaccine during the time when Omicron was the prevalent variant. More than 4,000 children in this age range have participated in the companies’ COVID-19 vaccine clinical trial to date.
The companies have also submitted an application to the European Medicines Agency for a booster dose in this age group and plan to file similarly with other regulatory agencies around the world. The Pfizer-BioNTech COVID-19 vaccine is currently the only COVID-19 vaccine authorized for use in the US for children in this age group. The vaccine is based on BioNTech’s proprietary mRNA technology, and the company is the Marketing Authorization Holder in the US, European Union, the UK, and Canada. BioNTech and Pfizer jointly hold EUAs or equivalents in the US and other countries.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
